Lumira Ventures
Canada&s;s leading health care &a; life sciences venture capital firm with a 30-year reputation building companies across North America.
Business Model:
Revenue: $19M
Employees: 11-50
Rankings
Detailed Lumira Ventures Information
Geographic Data
Address: 141 Adelaide Street
City: Toronto
State: ontario
Zip: M5H 3L5
Country: CA
Financial Info
Stage:
Raised Last:
$0
Raised Total:$255M
Social
Twitter
Linkedin
Crunchbase
Metrics
1,995,171Website Global Rank
10,464Website Monthly Traffic
Twitter Followers
Description
With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meeting significant unmet needs and creating transformation impact in communities worldwide. Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2018 | Exact Imaging | Venture Round | - |
| 12/2018 | Exact Imaging | Venture Round | - |
| 1/2018 | Celtaxsys | Series E | - |
| 6/2015 | Celtaxsys | Series D | 0 |
| 11/2017 | KalGene Pharmaceuticals | Series A | - |
| 1/2017 | Exact Imaging | Series C | 16.3M |
| 9/2017 | Engage Therapeutics | Series A | 23.6M |
| 6/2020 | HistoSonics | Series C | 40M |
| 11/2013 | Argos Therapeutics | Series E | 0 |
| 4/2012 | Argos Therapeutics | Series D | 0 |
| 11/2015 | Social Change Rewards | Venture Round | 2M |
| 5/2013 | Vendorlink.ca | Venture Round | - |
| 12/2021 | Specific Biologics | Seed Round | - |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 9/2018 | Osteopathy Quebec | Venture Round | - |
| 11/2014 | Osteopathy Quebec | Seed Round | - |
| 6/2018 | KisoJi Biotechnology | Series A | - |
| 2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 11/2015 | First Aid Shot Therapy | Series C | 24M |
| 10/2022 | PIC Therapeutics | Series A | 35M |
| 1/2018 | KisoJi Biotechnology | Venture Round | - |
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 11/2015 | BAROnova | Series D | 36.5M |
| 10/2008 | Pathfinder Therapeutics | Series A | 0 |
| 4/2014 | Cardiac Dimensions | Series A | 0 |
| 4/2019 | HistoSonics | Series C | 0 |
| 3/2013 | Corvia Medical | Series C | 10.7M |
| 2/2015 | G1 Therapeutics | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2014 | Cardiac Dimensions | Series A | 8.5M |
| 2/2021 | Notch Therapeutics | Series A | 85M |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 2/2021 | AmacaThera | Series A | 0 |
| 3/2015 | Vascular Pharmaceuticals | Series A | 9M |
| 10/2019 | AmacaThera | Seed Round | 2.7M |
| 9/2013 | Aurinia Pharmaceuticals | Post-IPO Equity | 5.8M |
| 7/2016 | Endotronix | Series C | 0 |
| 12/2022 | HistoSonics | Convertible Note | 85M |
| 11/2018 | Antios Therapeutics | Series A | 0 |
| 9/2017 | Edesa Biotech | Series A | 7M |
| 6/2015 | Gladius Pharmaceuticals | Series A | 3.3M |
| 3/2015 | Thrasos | Series D | 21M |
| 10/2016 | KisoJi Biotechnology | Series A | - |
| 3/2018 | KalGene Pharmaceuticals | Series A | 1.3M |
| 3/2015 | Cardiac Dimensions | Equity | 15.2M |
| 10/2012 | Thrasos | Series C | 35M |
| 9/2018 | Endotronix | Series D | 0 |
| 9/2020 | Cardiac Dimensions | Series C | 17.5M |
| 4/2012 | Forbius | Series A | - |
| 7/2014 | Corvia Medical | Series D | 34M |
| 6/2014 | Spinal Kinetics | Venture Round | 34M |
| 12/2021 | Viron | Series B | 50M |
| 4/2023 | Antiva Biosciences | Series E | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 5/2016 | Opsens | Post-IPO Equity | 5M |
| 1/2016 | Zymeworks | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 11/2013 | enGene | Venture Round | 13.3M |
| 10/2018 | Pediapharm | Post-IPO Equity | 47.6M |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 7/2015 | BAROnova | Venture Round | - |
| 2/2013 | BAROnova | Series C | 27.3M |
| 2/2018 | Exact Imaging | Series D | - |
| 1/2019 | enGene | Venture Round | - |
| 12/2021 | OncoMyx Therapeutics | Series B | 0 |
| 9/2014 | Forbius | Venture Round | - |
| 9/2022 | Damona Pharmaceuticals | Seed Round | 0 |
| 5/2017 | Forbius | Series B | - |
| 5/2016 | Osteopathy Quebec | Venture Round | - |
| 9/2017 | Stellar Biotechnologies | Post-IPO Equity | 0 |
| 12/2019 | Bright Angel Therapeutics | Seed Round | - |
| 5/2017 | Osteopathy Quebec | Venture Round | - |
| 2/2021 | Iterion Therapeutics | Series B | 17M |
| 12/2020 | Cyrano Therapeutics | Series A | 12.8M |
| 11/2014 | OsteoQC Inc | Seed Round | - |
| 5/2011 | U-Systems | Venture Round | 0 |
| 11/2018 | Gladius Pharmaceuticals | Venture Round | - |
| 1/2023 | Cardiac Dimensions | Series D | 35M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 4/2018 | Cardiac Dimensions | Series B | 39M |
| 5/2020 | IMV Inc | Post-IPO Equity | 18M |
| 1/2015 | enGene | Series B | 0 |
| 5/2020 | IMV | Post-IPO Equity | 25.1M |
| 4/2019 | Bardy Diagnostics | Series B | 35.5M |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 12/2021 | Specific Biologics | Seed Round | - |
| 12/2021 | OncoMyx Therapeutics | Series B | 0 |
| 12/2021 | Viron Inc. | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 5/2021 | BioTheryX | Series E | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
